Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)

Mohammad Afana; Mohammad Abu-Tineh; Anil Ellahie; Omar Ismail; Deena Sideeg; Afaf Albattah; Mohamed A Yassin

doi:10.7759/cureus.33612

Myocardial Infarction as an Initial Presentation of Essential Thrombocythemia With Calreticulin (CALR) Mutation (None Type 1, None Type 2)

Cureus. 2023 Jan 10;15(1):e33612. doi: 10.7759/cureus.33612. eCollection 2023 Jan.

Authors

Mohammad Afana¹, Mohammad Abu-Tineh¹, Anil Ellahie², Omar Ismail³, Deena Sideeg², Afaf Albattah², Mohamed A Yassin²

Affiliations

¹ Department of Oncology, Hematology and Bone Marrow Transplantation (BMT) Section, National Center for Cancer Care and Research, Doha, QAT.
² Department of Hematology, National Center for Cancer Care and Research, Doha, QAT.
³ Department of Hematology and Medical Oncology, National Center for Cancer Care and Research, Doha, QAT.

Abstract

Essential thrombocythemia (ET) is one of the classical Philadelphia-negative myeloproliferative neoplasms with different mutations that can be associated with it, like Janus kinase 2 (JAK2), myeloproliferative leukemia protein (MPL), and Calreticulin (CALR) (types 1 and 2). However, there is a lack in the literature concerning other types of CALR mutations and their clinical significance and prognosis. Here we report a 42-year-old male with type 2 diabetes who presented with an inferior ST-elevation myocardial infarction and thrombocytosis. The diagnosis of ET with CALR (neither type 1 nor type 2) was confirmed, which suggests the pathognomonic feature of this mutation.

Keywords: calreticulin; essential thrombocythemia; myeloproliferative neoplasm; myocardial infarction; thrombosis.

Publication types

Case Reports